Edgewise

Edgewise develops oral small molecules for muscular dystrophies. Its lead inhibitor aims to prevent muscle damage and preserve long-term function.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2021
Stage of Initial Investment
Series C
Initial Investment Year
2020